08Sep 2024
Anti-VEGF Therapy Shows Limited Impact on Post-Vitrectomy Edema

Anti-VEGF Therapy Shows Limited Impact on Post-Vitrectomy Edema

Anti-vascular endothelial growth factor (VEGF) therapy significantly reduced central retinal thickness (CRT) in post-vitrectomy macular edema (PVME) patients, from 509.9 ± 157.2 μm to 401.2 ± 172.1 μm (P < 0.001). In comparison, CRT decreased from 406.1 ± 96.1 μm to 355.1 ± 126.0 μm (P = 0.008) in patients not receiving anti-VEGF treatment. Best-corrected visual acuity (BCVA) improved in both groups, with significant improvements noted at 1, 2, and 3 months in the non-anti-VEGF group and at 1 and 3 months in the anti-VEGF group. A thicker baseline CRT was associated with greater CRT reduction (β = 0.44; P < 0.001). The study concluded that while anti-VEGF therapy reduces CRT, its effect on BCVA in the early postoperative period is limited.

  • #ophthalmology

Like

Save

Share